(2009). AM: Established, emerging and future roles of PET/CT in the management of colorectal cancer. Clin Radiol
(1981). AM: Localization of human tumour xenografts after i.v. administration of radiolabeled monoclonal antibodies.
(2006). Bleichrodt RP: Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis.
(2006). Bockisch A: False-positive FDG PET uptake–the role of PET/CT. Eur Radiol
(2010). Boerman OC: A novel facile method of labeling octreotide with (18)F-fluorine. J Nucl Med
(2010). Boerman OC: Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice.
(2010). Boerman OC: Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. Mol Cancer Ther
(2009). Boerman OC: Spatial resolution and sensitivity of the Inveon smallanimal PET scanner.
(2009). Bonomo L: Imaging of peritoneal carcinomatosis with FDG PET-CT: diagnostic patterns, case examples and pitfalls. Abdom Imaging
(2008). Chang CH: Multifunctional antibodies by the Dock-and-Lock method for improved cancer imaging and therapy by pretargeting.
(2006). Chang CH: Stably tethered multifunctional structures of defined composition made by the dock and lock method for use in cancer targeting. Proc Natl Acad Sci USA
(2003). Corstens FH: Pretargeted radioimmunotherapy of cancer: progress step by step.
(2007). Deandreis D: The role of 18F-fluoro-deoxy-glucose positron emission tomography (FDG-PET) in the management of patients with colorectal cancer.
(1984). Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by Schoffelen et al.
(2009). DM: A novel method of 18F radiolabeling for PET.
(1987). DM: Antibody protein dose and radioimmunodetection of GW-39 human colon tumor xenografts.
(2006). DM: Bispecific antibody pretargeting PET (immunoPET) with an 124I-labeled haptenpeptide.
(2000). DM: Experimental pretargeting studies of cancer with a humanized anti-CEA × murine anti-[In-DTPA] bispecific antibody construct and a (99 m)Tc-/(188)Re-labeled peptide. Bioconjug Chem
(2002). DM: Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol Cancer Ther
(2000). Dynamic radiology of the abdomen: normal and pathologic anatomy. 5 edition.
(2007). Even-Sapir E: Benign nonphysiologic lesions with increased 18F-FDG uptake on PET/CT: characterization and incidence.
(2007). Ferron-Orihuela A: Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer.
(1985). Frincke JM: Antibodies against metal chelates. Nature
(2001). Global cancer statistics in the year 2000. Lancet Oncol
(1989). Goldenberg DM: Influence of animal host and tumor implantation site on radio-antibody uptake in the GW-39 human colonic cancer xenograft.
(2008). Goldenberg DM: Metastatic human colonic carcinoma: molecular imaging with pretargeted SPECT and PET in a mouse model. Radiology
(2005). Goldenberg DM: Signal amplification in molecular imaging by pretargeting a multivalent, bispecific antibody. Nat Med
(2006). Halkar RK: Gastrointestinal tract malignancies and positron emission tomography: an overview. Semin Nucl Med
(1990). HJ: Murine monoclonal antibodies against carcinoembryonic antigen: immunological, pharmacokinetic, and targeting properties in humans. Cancer Res
(2006). Impact of animal handling on the results of 18F-FDG PET studies in mice.
(1989). In vitro and in vivo targeting of radiolabeled monovalent and divalent haptens with dual specificity monoclonal antibody conjugates: enhanced divalent hapten affinity for cell-bound antibody conjugate.
(2006). JC: Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. Eur J Surg Oncol
(2010). KM: [18F]FDG PET/CT imaging of colorectal cancer: a pictorial review. Postgrad Med J
(2009). Langsteger W: Detection of histologically proven peritoneal carcinomatosis with fused 18F-FDG-PET/MDCT.
(2004). Meterissian S: Positron emission tomography and colorectal carcinoma: an update.
(2004). Metser U: Detection of recurrence in patients with rectal cancer: PET/CT after abdominoperineal or anterior resection. Radiology
(2001). Penninckx F: Clinical value of whole-body emission tomography in potentially curable colorectal liver metastases.
(1990). Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors. Cancer Res
(1978). Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6adiphrenylglycoluril. Biochem Biophys Res Commun
(1990). Recognition of imidazole and histamine derivatives by monoclonal antibodies. Mol Immunol
(1986). Resection of the liver for colorectal carcinoma metastases: a multi-institutional study of patterns of recurrence. Surgery
(2005). Ruers TJ: The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. Cancer
(2007). Thun MJ: Cancer statistics,
(1986). Tumor size: effect on monoclonal antibody uptake in tumor models.
(2009). WJ: Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study.